Literature DB >> 10718941

Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study.

K Hino1, Y Yamaguchi, D Fujiwara, Y Katoh, M Korenaga, M Okazaki, M Okuda, K Okita.   

Abstract

We prospectively examined whether the complexity of hepatitis C virus (HCV) quasispecies is related to the response to interferon (IFN) therapy. Among 64 patients who had histologically proven chronic hepatitis and were treated with natural IFN-alpha, 53 patients were analysed. The other 11 patients discontinued therapy because of adverse effects of IFN. The complexity of the hypervariable region 1 (HVR 1) in quasispecies was determined using both clone number determined by fluorescence single-strand conformation polymorphism (SSCP) and nucleotide diversity determined by direct sequencing. These parameters were measured not only before treatment but also at completion and 6 months after therapy, if serum HCV RNA was detectable. This population of patients was different from the general Japanese population with regard to the high prevalence of patients infected with genotype 2a or 2b (49%), who had a higher viral load than those with genotype 1b (P = 0.021). Twenty-two patients (41.5%) were sustained responders. Genotype non-1b (P = 0.0009) and a smaller clone number (P = 0.008) were significantly associated with a sustained response. In multivariate analysis, these variables were independently associated with a sustained response (i.e. genotype: odds ratio 6.84, 95% CI 1.84-30. 12; and clone number: odds ratio 1.26, 95% CI 0.99-1.68). The clone number and nucleotide diversity did not change significantly between pretreatment and at completion or 6 months after therapy. These results suggest that lower complexity of HVR 1 quasispecies predicts a preferable response to IFN therapy that is independent of viral load, especially in the population of the relatively high prevalence of patients infected with genotype 2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718941     DOI: 10.1046/j.1365-2893.2000.00196.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  12 in total

1.  Significance of pretreatment analysis of hepatitis C virus genotype 1b hypervariable region 1 sequences to predict antiviral outcome.

Authors:  Catherine Gaudy; Alain Moreau; Pascal Veillon; Stephanie Temoin; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

2.  Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.

Authors:  Javier Salmerón; Paloma Muñoz De Rueda; Angela Ruiz-Extremera; Jorge Casado; Carlos Huertas; Maria Del Carmen Bernal; Luis Rodríguez; Angel Palacios
Journal:  Dig Dis Sci       Date:  2006-05       Impact factor: 3.199

Review 3.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C.

Authors:  Jian Wang; Gui-Ju Xiang; Bing-Xiang Liu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

5.  Wide range of quasispecies diversity during primary hepatitis C virus infection.

Authors:  Belinda L Herring; Rose Tsui; Lorraine Peddada; Michael Busch; Eric L Delwart
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Plasma and liver hepatitis C virus variability in patients coinfected with human immunodeficiency virus.

Authors:  Anne-Christine Jouvencel; Didier Neau; Muriel Faure; Martine Neau; Christophe Martinaud; Elisabeth Legrand; Pascale Trimoulet; Isabelle Garrigue; Brigitte Le Bail; Paulette Bioulac-Sage; Michel Dupon; Jean-Marie Ragnaud; Herve Fleury; Marie-Edith Lafon
Journal:  J Clin Microbiol       Date:  2006-05       Impact factor: 5.948

Review 7.  Epistatic connectivity among HCV genomic sites as a genetic marker of interferon resistance.

Authors:  James Lara; Yury Khudyakov
Journal:  Antivir Ther       Date:  2012-12-07

8.  HCV replication in PBMC and its influence on interferon therapy.

Authors:  Guo-Zhong Gong; Li-Ying Lai; Yong-Fang Jiang; Yan He; Xian-Shi Su
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

9.  Anti-HCV reactive volunteer blood donors distribution character and genotypes switch in Xi'an, China.

Authors:  Qiao-hong Yue; Xian-qing Zhang; Yu Shang; Yao-zhen Chen; Wen-li Sun; Min-quan Su; Shi-jie Mu; Xiao-ke Hao; Xing-bin Hu
Journal:  Virol J       Date:  2010-08-10       Impact factor: 4.099

10.  High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.

Authors:  Xiaofeng Fan; Qing Mao; Donghui Zhou; Yang Lu; Jianwei Xing; Yanjuan Xu; Stuart C Ray; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-12       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.